Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBB-2
- Development stage
- Preclinical
- Lead developer
- Multiverse Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
BBB-2 (also known as BBB-2 Ab) is a preclinical-stage monoclonal antibody being developed by Multiverse Pharma. It is specifically designed for applications in neurological diseases and neuro-oncology. While the specific molecular target has not been publicly disclosed, the 'BBB' designation in the company's pipeline typically refers to the blood-brain barrier, suggesting the antibody may utilize a specialized delivery platform or target central nervous system (CNS) specific pathology. The program is currently in the preclinical phase of development as part of Multiverse Pharma's focus on multispecific and CNS-penetrant biologics.
Beyond the preview
Go deeper on BBB-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBB-2.